HK1247120A1 - 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 - Google Patents

用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 Download PDF

Info

Publication number
HK1247120A1
HK1247120A1 HK18106821.2A HK18106821A HK1247120A1 HK 1247120 A1 HK1247120 A1 HK 1247120A1 HK 18106821 A HK18106821 A HK 18106821A HK 1247120 A1 HK1247120 A1 HK 1247120A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
ocular
pharmaceutically acceptable
certain embodiments
treatment
Prior art date
Application number
HK18106821.2A
Other languages
English (en)
Chinese (zh)
Inventor
A‧H-P‧克勞斯
A‧H-P‧克劳斯
Original Assignee
艾克瑟罗视觉股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾克瑟罗视觉股份有限公司 filed Critical 艾克瑟罗视觉股份有限公司
Publication of HK1247120A1 publication Critical patent/HK1247120A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK18106821.2A 2015-07-08 2016-07-07 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 HK1247120A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
HK1247120A1 true HK1247120A1 (zh) 2018-09-21

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106821.2A HK1247120A1 (zh) 2015-07-08 2016-07-07 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物

Country Status (21)

Country Link
US (3) US10413535B2 (https=)
EP (1) EP3319639B1 (https=)
JP (2) JP6752276B2 (https=)
KR (2) KR20220062688A (https=)
CN (1) CN107921136A (https=)
AU (1) AU2016290197B2 (https=)
BR (1) BR112018000112A2 (https=)
CA (1) CA2989522C (https=)
CL (1) CL2018000057A1 (https=)
ES (1) ES2835274T3 (https=)
HK (1) HK1247120A1 (https=)
IL (2) IL256770B (https=)
MA (2) MA42016A1 (https=)
MX (1) MX385229B (https=)
MY (1) MY187552A (https=)
PL (1) PL3319639T3 (https=)
RU (1) RU2018103940A (https=)
TN (1) TN2017000538A1 (https=)
UA (1) UA123728C2 (https=)
WO (1) WO2017006272A1 (https=)
ZA (1) ZA201708601B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
EP3624773A4 (en) * 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
MX2022001062A (es) * 2019-07-26 2022-02-14 Allegro Pharmaceuticals Llc Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20230110514A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
UA123728C2 (uk) 2021-05-26
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17
RU2018103940A3 (https=) 2019-09-03
CA2989522C (en) 2022-10-18
IL256770A (en) 2018-03-29
KR20220062688A (ko) 2022-05-17
KR20180041122A (ko) 2018-04-23
ES2835274T3 (es) 2021-06-22
IL280827A (en) 2021-04-29
AU2016290197A1 (en) 2018-01-04
MX2017017163A (es) 2018-08-09
WO2017006272A1 (en) 2017-01-12
CA2989522A1 (en) 2017-01-12
US20200000786A1 (en) 2020-01-02
JP2018521126A (ja) 2018-08-02
JP2020121985A (ja) 2020-08-13
PL3319639T3 (pl) 2021-03-08
AU2016290197B2 (en) 2021-07-22
CN107921136A (zh) 2018-04-17
ZA201708601B (en) 2019-05-29
TN2017000538A1 (en) 2019-04-12
US20200405703A1 (en) 2020-12-31
JP6752276B2 (ja) 2020-09-09
EP3319639A1 (en) 2018-05-16
KR102440162B1 (ko) 2022-09-02
MY187552A (en) 2021-09-29
RU2018103940A (ru) 2019-08-08
MX385229B (es) 2025-03-14
BR112018000112A2 (pt) 2018-09-04
IL256770B (en) 2021-02-28
MA42016A1 (fr) 2018-03-30
US20180200240A1 (en) 2018-07-19
CL2018000057A1 (es) 2018-06-22
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
US10751334B2 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
US8642067B2 (en) Methods and compositions for intraocular administration to treat ocular conditions
US20040198829A1 (en) Prostanoids augment ocular drug penetration
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
JP7624220B2 (ja) 自己抗体媒介性眼疾患の治療および診断
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
WO2021260430A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US20150307619A1 (en) Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
US20250367130A1 (en) Thermoresponsive hydrogel containing metal-organic framework particles for noninvasive ocular drug delivery